Valneva SE
VALN8.485USD
+0.125+1.50%
收盘 12/24, 13:00（美东）报价延迟15分钟
1.38B总市值
亏损市盈率 TTM
关于 Valneva SE 公司
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Valneva SE简介
公司代码VALN
公司名称Valneva SE
上市日期Jun 28, 2007
CEOLingelbach (Thomas)
员工数量- -
证券类型Depository Receipt
年结日Jun 28
公司地址6, Rue Alain Bombard
城市SAINT-HERBLAIN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家France
邮编44800
电话33228073710
网址https://valneva.com/
公司代码VALN
上市日期Jun 28, 2007
CEOLingelbach (Thomas)
Valneva SE公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Hanneke Schuitemaker
Dr. Hanneke Schuitemaker
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Kathrin U. Jansen, Ph.D.
Dr. Kathrin U. Jansen, Ph.D.
Director
Director
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ms. Daniele Guyot-Caparros
Ms. Daniele Guyot-Caparros
Independent Director
Independent Director
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Hanneke Schuitemaker
Dr. Hanneke Schuitemaker
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Kathrin U. Jansen, Ph.D.
Dr. Kathrin U. Jansen, Ph.D.
Director
Director
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
IXIARO
94.07M
55.47%
Third party products
33.19M
19.57%
DUKORAL
32.30M
19.05%
Chikungunya VLA1553
3.70M
2.18%
Others
1.13M
0.67%
Unallocated
704.00K
0.42%
地区USD
名称
营收
占比
United States
48.59M
28.66%
Canada
32.32M
19.06%
United Kingdom
19.49M
11.49%
Germany
18.37M
10.84%
Austria
15.90M
9.37%
其他
34.91M
20.58%
业务
地区
业务USD
名称
营收
占比
IXIARO
94.07M
55.47%
Third party products
33.19M
19.57%
DUKORAL
32.30M
19.05%
Chikungunya VLA1553
3.70M
2.18%
Others
1.13M
0.67%
Unallocated
704.00K
0.42%
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Novo Holdings A/S
2.73%
Frazier Life Sciences Management, L.P.
2.67%
General American Investors Company, Inc.
0.41%
Wells Fargo Advisors
0.18%
Marshall Wace LLP
0.04%
其他
93.97%
持股股东
持股股东
占比
Novo Holdings A/S
2.73%
Frazier Life Sciences Management, L.P.
2.67%
General American Investors Company, Inc.
0.41%
Wells Fargo Advisors
0.18%
Marshall Wace LLP
0.04%
其他
93.97%
股东类型
持股股东
占比
Venture Capital
2.73%
Private Equity
2.67%
Investment Advisor
0.47%
Research Firm
0.22%
Investment Advisor/Hedge Fund
0.04%
Hedge Fund
0.02%
其他
93.85%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
30
4.53M
5.58%
+3.61M
2025Q2
25
665.50K
0.82%
-300.83K
2025Q1
28
666.20K
0.82%
-333.59K
2024Q4
27
820.97K
1.18%
-47.15K
2024Q3
26
836.06K
1.21%
+31.78K
2024Q2
28
742.08K
1.07%
+162.52K
2024Q1
32
513.10K
0.74%
-47.53K
2023Q4
30
421.64K
0.61%
-110.65K
2023Q3
32
418.35K
0.60%
-285.66K
2023Q2
33
378.64K
0.55%
-602.57K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Novo Holdings A/S
2.38M
2.92%
+2.38M
--
Jun 30, 2025
Frazier Life Sciences Management, L.P.
1.46M
1.8%
+1.46M
--
Jun 30, 2025
General American Investors Company, Inc.
354.36K
0.44%
--
--
Jun 30, 2025
Wells Fargo Advisors
245.18K
0.3%
+1.96K
+0.81%
Jun 30, 2025
Ironwood Investment Management, LLC
25.14K
0.03%
+113.00
+0.45%
Jun 30, 2025
Morgan Stanley & Co. International Plc
6.54K
0.01%
+2.82K
+75.62%
Jun 30, 2025
Citadel Advisors LLC
35.74K
0.04%
+8.52K
+31.30%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
1.48K
0%
--
--
Jun 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Valneva SE的前五大股东是谁？
Valneva SE 的前五大股东如下：
Novo Holdings A/S持有股份：2.38M，占总股份比例：2.92%。
Frazier Life Sciences Management, L.P.持有股份：1.46M，占总股份比例：1.80%。
General American Investors Company, Inc.持有股份：354.36K，占总股份比例：0.44%。
Wells Fargo Advisors持有股份：245.18K，占总股份比例：0.30%。
Ironwood Investment Management, LLC持有股份：25.14K，占总股份比例：0.03%。
Novo Holdings A/S持有股份：2.38M，占总股份比例：2.92%。
Frazier Life Sciences Management, L.P.持有股份：1.46M，占总股份比例：1.80%。
General American Investors Company, Inc.持有股份：354.36K，占总股份比例：0.44%。
Wells Fargo Advisors持有股份：245.18K，占总股份比例：0.30%。
Ironwood Investment Management, LLC持有股份：25.14K，占总股份比例：0.03%。
Valneva SE的前三大股东类型是什么？
Valneva SE 的前三大股东类型分别是：
Novo Holdings A/S
Frazier Life Sciences Management, L.P.
General American Investors Company, Inc.
Novo Holdings A/S
Frazier Life Sciences Management, L.P.
General American Investors Company, Inc.
有多少机构持有Valneva SE(VALN)的股份？
截至2025Q3，共有30家机构持有Valneva SE的股份，合计持有的股份价值约为4.53M，占公司总股份的5.58%。与2025Q2相比，机构持股有所增加，增幅为4.77%。
哪个业务部门对Valneva SE的收入贡献最大？
在FY2024，IXIARO业务部门对Valneva SE的收入贡献最大，创收94.07M，占总收入的55.47%。
